Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IGSC 20% Flexible Dosing in Primary Immunodeficiency
NCT03814798Phase 3Withdrawn
- Sponsor
- Grifols
- Start
- Dec 2019
- Primary completion
- Sep 2020
- Modality
- Biologic, rProtein (Recombinant Protein)
- Countries
- 1
01
Overview
A Phase 3 trial of immune globulin subcutaneous, human-klhw in primary immunodeficiency (PI), sponsored by Grifols. Planned start Dec 2019; status: withdrawn.
02
Drugs
immune globulin subcutaneous, human-klhw
03
Conditions
primary immunodeficiency (PI)
Beyond the preview
Go deeper on NCT03814798.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03814798.